Condition: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Sponsor: Regeneron Pharmaceuticals
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2. The study is looking at several other research questions, including: * Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood * To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| The City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Recruiting |
| Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| H. Lee Moffitt Cancer Center | Tampa, Florida, United States | Completed |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute Brookline Avenue | Boston, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| The Ohio State University Wexner Medical Center | Columbus, Ohio, United States | Recruiting |
| Perelman School of Medicine at the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04590326